Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab
Among patients undergoing nivolumab treatment, CPS ≥1 was significantly associated with longer survival outcomes in CLDN18.2-positive patients, and a tendency toward improved Nivo-OS in TROP2-positive patients.
Authors
- Toru Kadono (ORCID: https://orcid.org/0000-0002-2898-4860)
- Takahito Awatsu (ORCID: https://orcid.org/0009-0004-9512-087X)
- Hidekazu Hirano (ORCID: https://orcid.org/0000-0003-1343-1419)
- A. Takashima
- Toshiharu Hirose (ORCID: https://orcid.org/0009-0002-3623-6691)
- A Nagahara
- NATSUKO OKITA
- KEN KATO
- HIROKAZU SHOJI
Institutions
- Juntendo University (JP)
- National Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18006
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00